364 related articles for article (PubMed ID: 24568095)
1. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
Chiricozzi A; Saraceno R; Chimenti MS; Guttman-Yassky E; Krueger JG
Expert Opin Ther Targets; 2014 May; 18(5):513-25. PubMed ID: 24568095
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
3. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-12, interleukin-23, and psoriasis: current prospects.
Torti DC; Feldman SR
J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
[TBL] [Abstract][Full Text] [Related]
5. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
Kim J; Krueger JG
Annu Rev Med; 2017 Jan; 68():255-269. PubMed ID: 27686018
[TBL] [Abstract][Full Text] [Related]
6. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting of interleukin-23p19 as effective treatment for psoriasis.
Levin AA; Gottlieb AB
J Am Acad Dermatol; 2014 Mar; 70(3):555-61. PubMed ID: 24373779
[TBL] [Abstract][Full Text] [Related]
8. Targeting IL-23 in human diseases.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Targets; 2010 Jul; 14(7):759-74. PubMed ID: 20536413
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
[TBL] [Abstract][Full Text] [Related]
10. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis.
Nakajima K
J Dermatol; 2012 Mar; 39(3):219-24. PubMed ID: 22352845
[TBL] [Abstract][Full Text] [Related]
11. Cellular sources of IL-17 in psoriasis: a paradigm shift?
Keijsers RR; Joosten I; van Erp PE; Koenen HJ; van de Kerkhof PC
Exp Dermatol; 2014 Nov; 23(11):799-803. PubMed ID: 25039885
[TBL] [Abstract][Full Text] [Related]
12. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.
Chan JR; Blumenschein W; Murphy E; Diveu C; Wiekowski M; Abbondanzo S; Lucian L; Geissler R; Brodie S; Kimball AB; Gorman DM; Smith K; de Waal Malefyt R; Kastelein RA; McClanahan TK; Bowman EP
J Exp Med; 2006 Nov; 203(12):2577-87. PubMed ID: 17074928
[TBL] [Abstract][Full Text] [Related]
13. Tildrakizumab for the treatment of psoriasis.
Bangert C; Kopp T
Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
[TBL] [Abstract][Full Text] [Related]
14. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model.
Nakajima K; Kanda T; Takaishi M; Shiga T; Miyoshi K; Nakajima H; Kamijima R; Tarutani M; Benson JM; Elloso MM; Gutshall LL; Naso MF; Iwakura Y; DiGiovanni J; Sano S
J Immunol; 2011 Apr; 186(7):4481-9. PubMed ID: 21346238
[TBL] [Abstract][Full Text] [Related]
15. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Kivelevitch DN; Menter A
Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.
Ma HL; Napierata L; Stedman N; Benoit S; Collins M; Nickerson-Nutter C; Young DA
Arthritis Rheum; 2010 Feb; 62(2):430-40. PubMed ID: 20112373
[TBL] [Abstract][Full Text] [Related]
17. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
18. IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis.
Bartlett BL; Moody MN; Tyring SK
Skin Therapy Lett; 2008; 13(8):1-4. PubMed ID: 19145382
[TBL] [Abstract][Full Text] [Related]
19. IL-17 targeted therapies for psoriasis.
Chiricozzi A; Krueger JG
Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
